Evaxion A/S FY2026 EPS Forecast Reduced by HC Wainwright

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) – Equities research analysts at HC Wainwright decreased their FY2026 EPS estimates for Evaxion A/S in a research note issued on Friday, August 21st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($2.00) per share for the year, down from their previous forecast of ($0.50). The consensus estimate for Evaxion A/S’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Evaxion A/S’s FY2027 earnings at $0.00 EPS, FY2028 earnings at $1.50 EPS, FY2029 earnings at $2.50 EPS and FY2030 earnings at $3.00 EPS.

Separately, Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evaxion A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Evaxion A/S Stock Up 2.7%

Shares of EVAX stock opened at $3.40 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. Evaxion A/S has a one year low of $2.52 and a one year high of $12.15. The company’s fifty day moving average price is $3.13 and its 200-day moving average price is $3.56. The company has a market capitalization of $28.36 million, a price-to-earnings ratio of -2.81 and a beta of 0.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EVAX. Wesbanco Bank Inc. bought a new stake in shares of Evaxion A/S during the fourth quarter valued at approximately $48,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Evaxion A/S in the fourth quarter worth $38,000. SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S during the fourth quarter worth $72,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S during the first quarter worth $112,000. Finally, Renaissance Technologies LLC purchased a new position in Evaxion A/S during the first quarter valued at $146,000. 11.04% of the stock is currently owned by institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.